Globus Medical, Inc. with ticker code (GMED) have now 13 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $100.00 and $80.00 calculating the mean target price we have $90.54. Given that the stocks previous close was at $81.97 this indicates there is a potential upside of 10.5%. The 50 day moving average now sits at $72.28 while the 200 day moving average is $63.85. The company has a market cap of 11.01B. The stock price is currently at: $80.88 USD
The potential market cap would be $12,164,621,250 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 130.45, revenue per share of $18.22 and a 4.73% return on assets.
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions. The Company’s product categories include Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. Enabling Technologies is comprised of imaging, navigation and robotics (INR) solutions for assisted surgery.
